Pharma Ally Kurt Schrader Cashes In on K Street Schrader’s new lobbying employer works for numerous drug companies like Pfizer and Sanofi, plus industry trade association PhRMA.
Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs, House Report Finds The largest drugmakers spent $56 billion more on stock buybacks and dividends than on research and development from 2016 to 2020, according to a new House committee report.
